Neonatal alloimmune thrombocytopaenia associated with maternal HLA antibodies

BMJ Case Rep. 2017 Jul 5:2017:bcr2016218269. doi: 10.1136/bcr-2016-218269.

Abstract

Neonatal alloimmune thrombocytopaenia (NAIT) generally results from platelet opsonisation by maternal antibodies against fetal platelet antigens inherited from the infant's father. Newborn monochorionic twins presented with petechial haemorrhages at 10 hours of life, along with severe thrombocytopaenia. Despite the initial treatment with platelet transfusions and intravenous immunoglobulin, they both had persistent thrombocytopaenia during their first 45 days of life. Class I human leucocyte antigen (HLA) antibodies with broad specificity against several HLA-B antigens were detected in the maternal serum. Weak antibodies against HLA-B57 and HLA-B58 in sera from both twins supported NAIT as the most likely diagnosis. Platelet transfusion requirements of the twins lasted for 7 weeks. Transfusion of HLA-matched platelet concentrates was more efficacious to manage thrombocytopaenia compared with platelet concentrates from random donors. Platelet genotyping and determination of HLA antibody specificity are needed to select compatible platelet units to expedite safe recovery from thrombocytopaenia in NAIT.

Keywords: emergency medicine; general surgery; mediacal education; resuscitation; surgery; trauma.

Publication types

  • Case Reports

MeSH terms

  • Antibodies / blood*
  • Antigens, Human Platelet / blood*
  • Blood Platelets / metabolism*
  • Female
  • Genotype
  • HLA-B Antigens / blood*
  • Humans
  • Immunoglobulins, Intravenous
  • Infant, Newborn
  • Maternal-Fetal Exchange*
  • Platelet Transfusion*
  • Pregnancy
  • Thrombocytopenia, Neonatal Alloimmune / blood
  • Thrombocytopenia, Neonatal Alloimmune / diagnosis*
  • Thrombocytopenia, Neonatal Alloimmune / etiology
  • Thrombocytopenia, Neonatal Alloimmune / therapy
  • Twins

Substances

  • Antibodies
  • Antigens, Human Platelet
  • HLA-B Antigens
  • HLA-B57 antigen
  • HLA-B58
  • Immunoglobulins, Intravenous